BMO Capital downgrades Tourmaline Bio stock rating following Novartis acquisition news

Novartis has agreed to acquire Tourmaline Bio for approximately $1.4 billion, or $48 per share, to gain its IL-6-targeting antibody, pacibekitug, for cardiovascular disease, with the deal expected to close by Q4 2025. Following this announcement, multiple analysts, including BMO Capital, Jefferies, Guggenheim, and Wedbush, downgraded Tourmaline Bio to 'Market Perform,' 'Hold,' or 'Neutral,' aligning their price targets with the acquisition price. This reflects the stock's recent nearly 58% surge, trading near the deal value and its 52-week high, indicating limited further upside for shareholders.

Analysis

Novartis has entered a definitive agreement to acquire Tourmaline Bio for approximately $1.4 billion, or $48.00 per share, a strategic move to gain access to pacibekitug, an IL-6-targeting antibody for cardiovascular disease. The market has swiftly priced in this deal, with Tourmaline's stock (TRML) surging nearly 58% in the past week to trade at $47.61, marginally below the acquisition price and its 52-week high. Consequently, a consensus has formed among analysts to downgrade TRML, with BMO Capital, Jefferies, Guggenheim, and Wedbush all moving their ratings to 'Market Perform,' 'Hold,' or 'Neutral.' This sentiment shift is not a reflection of the asset's quality but an acknowledgement that near-term upside for the stock is now capped by the transaction terms. Analysts have concurrently raised their price targets to align with the $48.00 deal price. The acquisition is expected to close smoothly by the fourth quarter of 2025, as analysts do not foresee material anti-trust concerns given the lack of overlapping programs in Novartis's existing pipeline.

Key Decisions for Investors

• Investors holding Tourmaline Bio should recognize that the stock is now an M&A arbitrage play, with its current price of $47.61 reflecting the full $48.00 acquisition value and implying minimal further upside before the expected Q4 2025 close.
• Initiating new long positions in TRML presents an unfavorable risk-reward profile, as the potential gain is negligible while capital would be tied up for over a year and subject to deal-break risk.
• For Novartis investors, this is a strategic bolt-on acquisition that enhances its cardiovascular pipeline but is unlikely to materially impact near-term financials or stock performance, making the long-term clinical development of pacibekitug the key value driver to monitor.